narmac  - I have given your query some thought a number of times. One day we hope RVX will be acquired and we all walk away with our pockets overflowing. In order for that to happen BoM has to be successful whether or not the secondary studies have been furthered. IMO RVX's management has done the correct thing by focusing on what is going to drive value for the shareholders...BoM. They may have liked to do all kinds of trials but money has always been a challenge for this little biotech. I can reasonably go further here and say money is a challenge for any Canadian biotech. 

So why would they go through the exercise of designing and filing other trials when they don't have the dollars to pursue them? Possibly because their potential suitors would find this company more attractive if they could hit the ground running upon an acquisition. It's the only logical explanation I could come up with for a company that has had so many challenges around funding a current trial. I'm open to any logical opinions that others have.

tada